MXPA04000839A - Metodos y composiciones para el tratamiento de enfermedades oftalmicas. - Google Patents

Metodos y composiciones para el tratamiento de enfermedades oftalmicas.

Info

Publication number
MXPA04000839A
MXPA04000839A MXPA04000839A MXPA04000839A MXPA04000839A MX PA04000839 A MXPA04000839 A MX PA04000839A MX PA04000839 A MXPA04000839 A MX PA04000839A MX PA04000839 A MXPA04000839 A MX PA04000839A MX PA04000839 A MXPA04000839 A MX PA04000839A
Authority
MX
Mexico
Prior art keywords
treatment
eye diseases
integrin inhibitors
eye
compositions
Prior art date
Application number
MXPA04000839A
Other languages
English (en)
Inventor
Haunschild Jutta
Original Assignee
Merck Patent Gesellscahft Mit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gesellscahft Mit filed Critical Merck Patent Gesellscahft Mit
Publication of MXPA04000839A publication Critical patent/MXPA04000839A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

Metodos y composiciones para la profilaxis y/o tratamiento de enfermedades oftalmicas usando antagonistas de los receptores de integrina av'3 y/o aV'p5. Las composiciones pueden ser nanoparticulas y se administran en el ojo por inyeccion en el cuerpo vitreo.
MXPA04000839A 2001-08-01 2002-07-03 Metodos y composiciones para el tratamiento de enfermedades oftalmicas. MXPA04000839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885101P 2001-08-01 2001-08-01
PCT/EP2002/007377 WO2003013511A1 (en) 2001-08-01 2002-07-03 Integrin inhibitors for the treatment of eye diseases

Publications (1)

Publication Number Publication Date
MXPA04000839A true MXPA04000839A (es) 2004-05-14

Family

ID=23195644

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000839A MXPA04000839A (es) 2001-08-01 2002-07-03 Metodos y composiciones para el tratamiento de enfermedades oftalmicas.

Country Status (20)

Country Link
US (2) US20040198644A1 (es)
EP (1) EP1411926B1 (es)
JP (1) JP2005504757A (es)
KR (1) KR20040028966A (es)
CN (1) CN1536998A (es)
AR (1) AR036199A1 (es)
AT (1) ATE296628T1 (es)
AU (1) AU2002319282B2 (es)
BR (1) BR0211604A (es)
CA (1) CA2456076C (es)
DE (1) DE60204466T2 (es)
DK (1) DK1411926T3 (es)
ES (1) ES2243744T3 (es)
HU (1) HUP0401605A3 (es)
MX (1) MXPA04000839A (es)
PL (1) PL207175B1 (es)
PT (1) PT1411926E (es)
RU (1) RU2311177C2 (es)
WO (1) WO2003013511A1 (es)
ZA (1) ZA200401598B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
CN102427816A (zh) 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
EA032552B1 (ru) 2012-03-16 2019-06-28 Дзе Джонс Хопкинс Юниверсити Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
EA030318B1 (ru) 2012-03-16 2018-07-31 Дзе Джонс Хопкинс Юниверсити Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) * 2012-05-08 2015-04-30 The Regents Of The University Of California Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CA3007198A1 (en) * 2015-12-04 2017-06-08 Janssen Biotech, Inc. Treatment of retinal degeneration using progenitor cells
AU2017359027A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Indazole derivatives as αV integrin antagonists
KR102307767B1 (ko) * 2019-03-11 2021-10-01 서울대학교병원 망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903921B2 (ja) * 1995-08-14 2012-03-28 ザ スクリプス リサーチ インスティチュート αＶβ５仲介血管形成の阻止に有効な方法及び組成物
DE19538741A1 (de) * 1995-10-18 1997-04-24 Merck Patent Gmbh Cyclopeptidderivate
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP2000516201A (ja) * 1996-05-31 2000-12-05 ザ スクリップス リサーチ インスティテュート 血管形成阻害方法及び血管形成阻害に有用な組成物
PL330241A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods of and compositions useful in inhibiting angiogenesis
DE19705450A1 (de) * 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP1061916A2 (en) * 1998-03-13 2000-12-27 Centaur Pharmaceuticals, Inc. Use os nitrone compounds for the inhibition of angiogenesis
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate

Also Published As

Publication number Publication date
US20060287225A1 (en) 2006-12-21
CA2456076C (en) 2011-08-23
DE60204466T2 (de) 2006-04-27
US20040198644A1 (en) 2004-10-07
PT1411926E (pt) 2005-10-31
ATE296628T1 (de) 2005-06-15
KR20040028966A (ko) 2004-04-03
CA2456076A1 (en) 2003-02-20
US7645736B2 (en) 2010-01-12
DE60204466D1 (de) 2005-07-07
ES2243744T3 (es) 2005-12-01
HUP0401605A3 (en) 2012-09-28
PL367959A1 (en) 2005-03-07
AR036199A1 (es) 2004-08-18
RU2311177C2 (ru) 2007-11-27
RU2004106527A (ru) 2005-07-10
BR0211604A (pt) 2004-08-24
CN1536998A (zh) 2004-10-13
EP1411926A1 (en) 2004-04-28
PL207175B1 (pl) 2010-11-30
AU2002319282B2 (en) 2007-06-28
JP2005504757A (ja) 2005-02-17
HUP0401605A2 (hu) 2004-11-29
EP1411926B1 (en) 2005-06-01
DK1411926T3 (da) 2005-08-29
ZA200401598B (en) 2004-11-17
WO2003013511A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
MXPA04000839A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
GEP20115205B (en) Controlled release sterile injectable aripiprazole formulation and method
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
MY134222A (en) NEW MEDICAMENT COMPOSITIONS BASED ON ANTICHOLINERGICALLY-EFFECTIVE COMPOUNDS AND ß-MIMETICS
TW200626148A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
WO2004019884A3 (en) Agents and methods for enhancing bone formation
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
WO2002041910A3 (en) Methods and compositions for the treatment of diseases of the eye
IL162515A0 (en) Substituted diketopiperazines as oxytocin antagonists
BR0307627A (pt) Métodos e composições para o tratamento de doenças do olho
BG108180A (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2002102978A3 (en) Human growth hormone antagonists
AU2003226765A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
WO2002069944A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
MXPA03008406A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina.
AU7476501A (en) New use of angiotensin ii antagonists
EP1480678A4 (en) TREATMENT OF OPHTHALMIC DISORDERS WITH UREA OR UREA DERIVATIVES